Compugen Reports Third Quarter 2020 Results

Go back to Compugen Reports Third Quarter 2020 Results

Compugen (CGEN) Reports In-Line Q3 EPS

November 5, 2020 9:15 AM EST

Compugen (NASDAQ: CGEN) reported Q3 EPS of ($0.09), in-line with the analyst estimate of ($0.09).

"We have reached an exciting milestone this quarter, initiating our biomarker-driven, Phase 1/2 triple combination study of our first-in-class anti-PVRIG antibody, COM701, with Bristol Myers Squibb's Opdivo® and their investigational TIGIT antibody, marking the evaluation of our DNAM... More